MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee Boong Lee, Man Seong Park, Yong Sung Kim, Hosun Park, Dong Sik Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.

Original languageEnglish
Article number778829
JournalFrontiers in immunology
Publication statusPublished - 2021 Nov 18

Bibliographical note

Funding Information:
This research was supported by the Mogam Institute for Biomedical Research and GC Pharma, Republic of Korea (Grant number: MG1141A). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Publisher Copyright:
Copyright © 2021 Lee, Jang, Kang, Park, Han, Nam, Kim, Lee, Cho, Kim, Oh, Ryu, Seok, Kim, Lee, Park, Kim, Park and Kim.


  • MG1141A
  • SARS-CoV-2
  • monoclonal antibody
  • outbreak
  • spike protein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants'. Together they form a unique fingerprint.

Cite this